Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Table 4 Incidence of gastrointestinal adverse events occurring in ≥ 10% of patients during the two year treatment period

	Percentage of patients with event
	Clodronate (n = 530)	Placebo (n = 539)
Nausea	27.0	29.8
Diarrhoea¹	19.9	10.0
Dyspepsia	15.6	13.3
Vomiting	14.7	13.1
Abdominal pain	13.6	10.5
Constipation	12.5	12.2
Stomatitis	8.4	10.2

ISSN: 1465-542X